A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
09/09/2022at 15:28

Top news from MedWatch this week

Miss anything?
Photo: MedWatch
by MIKKEL AABENHUS HEMMINGSEN

Monday

WS Audiology closes factory, lets 189 employees go

Ambu CEO wants more women in leadership

Tuesday

Demant establishes innovation unit in Kuala Lumpur

EU blocks Illumina acquisition of Grail

Leo Pharma’s energy contingency plan approved

Wednesday

Novo Nordisk licenses hypoglycemia drug from Zealand Pharma

Zealand CEO: Novo Nordisk is ”the perfect partner” to market rescue pen

Analyst: Zegalogue launch should be ”plug and play” for Novo Nordisk

Zealand Pharma intensifies partner hunt for other drug candidates

Bavarian Nordic raises expectations after another EU monkeypox vaccine order

Coloplast has a cost problem, says EVP of global operations

Thursday

Leo Pharma leaves the door open for acquisitions

Leo Pharma CEO: ”The strategy has started to crystalize and yield a return”

Friday

Coloplast’s new factories in Costa Rica will increase salary savings and reduce climate footprint

Novo Nordisk to launch cheaper version of long-acting insulin in US

Former Ambu employee stands trial for alleged insider trading


Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Foto: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”

For subscribers

Leo Pharma's Becki Morison urges the Danish Medicines Council to be more transparent about different committee candidates' impartiality issues. | Foto: Leo Pharma/pr
Pharma & biotech

Danish Medicines Council delays review of Leo Pharma's eczema treatment

Assessment of Leo Pharma’s tralokinumab is still dragging out at the Danish Medicines Council, which for a year has been unable to put together an expert committee due to the council’s impartiality policy. Leo Pharma calls for more transparency regarding the council’s challenges in that regard.

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Application Manager

  • Commercial Director

  • Clinical Operational Associate

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Principal Laboratory Technologist

  • Lead Data Architect

See all jobs

Jobs

  • Head of Regulatory Affairs Danmark

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Application Manager

  • Commercial Director

  • Clinical Operational Associate

  • Senior Regulatory Affairs Professional

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Principal Laboratory Technologist

  • Lead Data Architect

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge